These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A clinicopathological description of COVID-19-induced chilblains (COVID-toes) correlated with a published literature review. Kolivras A; Thompson C; Pastushenko I; Mathieu M; Bruderer P; de Vicq M; Feoli F; Harag S; Meiers I; Olemans C; Sass U; Dehavay F; Fakih A; Lam-Hoai XL; Marneffe A; Van De Borne L; Vandersleyen V; Richert B J Cutan Pathol; 2022 Jan; 49(1):17-28. PubMed ID: 34272741 [TBL] [Abstract][Full Text] [Related]
10. Management of pernio-like cutaneous manifestations in children during the outbreak of COVID-19. Gallizzi R; Sutera D; Spagnolo A; Bagnato AM; Cannavò SP; Grasso L; Guarneri C; Nunnari G; Mazza F; Pajno GB Dermatol Ther; 2020 Nov; 33(6):e14312. PubMed ID: 32949449 [TBL] [Abstract][Full Text] [Related]
11. Purple toes following critical COVID-19 infection. Ng AT; Miller A; Bodemer AA; Drolet BA; Arkin L Pediatr Dermatol; 2022 Sep; 39(5):815-817. PubMed ID: 36206217 [No Abstract] [Full Text] [Related]
12. Approach to Chilblains During the COVID-19 Pandemic [Formula: see text]. Ladha MA; Luca N; Constantinescu C; Naert K; Ramien ML J Cutan Med Surg; 2020; 24(5):504-517. PubMed ID: 32741218 [TBL] [Abstract][Full Text] [Related]
13. Lack of association between pandemic chilblains and SARS-CoV-2 infection. Gehlhausen JR; Little AJ; Ko CJ; Emmenegger M; Lucas C; Wong P; Klein J; Lu P; Mao T; Jaycox J; Wang E; ; Ugwu N; Muenker C; Mekael D; Klein RQ; Patrignelli R; Antaya R; McNiff J; Damsky W; Kamath K; Shon J; Ring AM; Yildirim I; Omer S; Ko AI; Aguzzi A; Iwasaki A Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217624 [TBL] [Abstract][Full Text] [Related]
14. COVID toes: where do we stand with the current evidence? Baeck M; Herman A Int J Infect Dis; 2021 Jan; 102():53-55. PubMed ID: 33075530 [TBL] [Abstract][Full Text] [Related]
15. [COVID-toes, a cutaneous sign of innate resistance to SARS-CoV-2]. Yatim A; Gilliet M Rev Med Suisse; 2021 Mar; 17(732):646-652. PubMed ID: 33793103 [TBL] [Abstract][Full Text] [Related]
16. No SARS-CoV-2 antibody response in 25 patients with pseudo-chilblains. Docampo-Simón A; Sánchez-Pujol MJ; Gimeno-Gascon A; Palazón-Cabanes JC; Juan-Carpena G; Vergara-De Caso E; González-Villanueva I; Blanes-Martínez M; Betlloch-Mas I Dermatol Ther; 2020 Nov; 33(6):e14332. PubMed ID: 32975345 [TBL] [Abstract][Full Text] [Related]
17. Cilostazol as a Treatment for COVID Toes: A Case Report. McClelland P; Gray BH Ann Vasc Surg; 2023 Apr; 91():76-80. PubMed ID: 36442709 [TBL] [Abstract][Full Text] [Related]
18. From Your Nose to Your Toes: A Review of Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic‒Associated Pernio. Arkin LM; Moon JJ; Tran JM; Asgari S; O'Farrelly C; Casanova JL; Cowen EW; Mays JW; Singh AM; Drolet BA; J Invest Dermatol; 2021 Dec; 141(12):2791-2796. PubMed ID: 34561087 [TBL] [Abstract][Full Text] [Related]
19. A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection. El Hachem M; Diociaiuti A; Concato C; Carsetti R; Carnevale C; Ciofi Degli Atti M; Giovannelli L; Latella E; Porzio O; Rossi S; Stracuzzi A; Zaffina S; Onetti Muda A; Zambruno G; Alaggio R J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2620-2629. PubMed ID: 32474947 [TBL] [Abstract][Full Text] [Related]